---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002889"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:45:41.634561+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Therapeutics Q1 net loss narrows to $23.0M; NASH and COVID programs on track

## Summary
- Cash, cash equivalents and investments $103.5M as of March 31, 2023, vs $125.8M at Dec 31, 2022.
- Net loss $23.0M ($0.53 per share) compared to $35.6M ($0.84) in Q1 2022.
- R&D expenses decreased to $18.1M from $31.7M YoY due to wind-down of STOPS and ASO programs.
- NASH gel cap formulation selected; Phase 2 IND filing remains on track for Q4 2023.
- COVID-19 protease inhibitor CTA submitted in UK; first-in-human dosing expected mid-2023.

## SEC filing metadata
- accession: 0001171843-23-002889
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/0001171843-23-002889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/f8k_050423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002889
- JSON: https://secwatch.observer/filing/0001171843-23-002889.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002889.txt

## Key facts
- Earnings Releases
  Aligos Therapeutics, Inc. reported first quarter 2023 results: net income $23.0 million, EPS $(0.53).
  - Period: first quarter 2023
  - Net income: $23.0 million
  - EPS: $(0.53)
  - Result: reported results
  source text: Net losses for the three months ended March 31, 2023, were $23.0 million or basic and diluted net loss per common share of $(0.53), compared to net losses of $35.6 million or basic and diluted net loss per common share of $(0.84) for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/0001171843-23-002889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.